The Patent Trial and Appeal Board said that some challenged claims of Miracor Medical SA’s patent that relates to medical care for normalizing and stabilizing cardiac function after a heart failure are unpatentable as obvious over prior art, in an inter partes review by Abbott Laboratories. The board said that some challenged claims are obvious over prior art titled “Development of Terumo Implantable Left Ventricular Assist System (T-ILVAS) with a Magnetically Suspended Centrifugal Pump,” and that discloses a rotary pump comprising a hydraulically mounted rotor. And the board denied Miracor’s motion to exclude evidence.
This summary was produced by Bloomberg ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.